GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after ...
By Bhanvi Satija and Prerna Bedi July 17 (Reuters) - GSK will halt development of an experimental drug to treat refractory ...
Stories by SWNS on MSN
Parrot keeps mimicking owner’s dad’s chronic cough
A Congo African grey parrot named Jack has become known for repeatedly imitating the chronic cough of her owner’s father, who ...
The FDA said the detection of Cyclospora in iceberg lettuce from Taylor Farms, initially linked to a multistate outbreak of cyclosporiasis, turned out to be a false positive. A th ...
GlobalData on MSN
GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid
The British pharma company will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.
Sonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The Readout ...
GSK said it decided to halt the development of an experimental drug as a treatment for chronic cough after the medicine missed the key goal in a late-stage clinical study. The U.K. drugmaker said ...
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...
Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored ...
U.S. stock futures dip amid AI chip selloff. Here are some stocks to watch on the day.
GSK plc provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in adults with refractory ...
GSK trades 42% below pharma peers as HIV injectables grow, Nuvalent adds oncology launches, and hep B catalyst nears.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results